Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CAT-1 CRISPR/Cas9 KO Plasmid (h): sc-403628
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CAT-1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CAT-1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CAT-1 Antibody (F-2): sc-515782
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CAT-1 CRISPR/Cas9 KO Plasmid (h) | sc-403628 | 20 µg | $397.00 |
Overview
SLC7A1 encodes CAT-1 (cationic amino acid transporter 1), a high-affinity plasma membrane transporter responsible for sodium-independent uptake of L-arginine, L-lysine, and L-ornithine. By controlling intracellular arginine availability, CAT-1 influences nitric oxide synthesis, polyamine metabolism, and mTOR- and redox-linked signaling that couple nutrient transport to cell growth and stress responses. CAT-1 activity also contributes to endothelial and immune cell function through regulation of arginine flux and downstream metabolic programs. Dysregulation of cationic amino acid transport has been associated with altered vascular biology, inflammation, and metabolic remodeling in disease-relevant cellular contexts.
CAT-1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SLC7A1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SLC7A1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SLC7A1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CAT-1 protein expression.
This CRISPR knockout system enables efficient generation of SLC7A1-deficient cell models for investigation of CAT-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SLC7A1 exon(s) critical for CAT-1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SLC7A1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CAT-1 CRISPR/Cas9 KO Plasmid (h) and CAT-1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SLC7A1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CAT-1 HDR Plasmid (h) and CAT-1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SLC7A1 homology arms to support homology-directed repair at defined SLC7A1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.